MSC Clinical Trials: What ISCT Dublin Revealed About Meniscal Repair, Mitochondrial Transfer, and Cell Sourcing

A medical review of MSC clinical trials 2026: key evidence from ISCT Dublin, a Japanese phase III synovial-MSC meniscal repair trial, bone marrow vs cord tissue OA data, and mitochondrial EV mechanisms.

Читать далее...

Stem Cell Therapy for Spinal Cord Injury: What 2026 Research Tells Us About MSC Therapy After SCI

Japan approved the world’s first MSC therapy for spinal cord injury in 2018. Here’s what six years of real-world data and 2026 mechanism research tell us about where MSC therapy for SCI actually stands.

Читать далее...

Stem Cell Therapy for Erectile Dysfunction: A Patient’s Guide to the 2026 Evidence

Diabetic ED, post-prostatectomy ED, PDE5 non-responders — here’s what 2026 trials and clinical experience show for stem cell therapy: who is a candidate, what the procedure looks like, what it costs, and what to expect.

Читать далее...

Allogeneic vs Autologous Stem Cells: What 2026 Evidence Says Is Better

2026 Q3 update on allogeneic vs autologous MSC: head-to-head trial data, donor-age impact, 2026 manufacturing advances, when each is preferred, the cost picture, and FAQ for patients in Thailand and Asia-Pacific.

Читать далее...

Stem Cell Therapy for Osteoporosis: What 2026 Research Means for Women After Menopause

Osteoporosis after menopause affects millions of women. New 2026 research shows mesenchymal stem cells and exosomes can rebuild bone density safely. Here’s what patients need to know.

Читать далее...

MSC Therapy for Burn Wounds and Chronic Skin Regeneration: 2026 Breakthroughs in Exosome-Based Healing

New 2026 research reveals UC-MSC exosomes combined with low-intensity pulsed ultrasound and curcumin-hydrogel systems achieve remarkable burn wound healing — including MRSA-infected wounds — through autophagy regulation, anti-scarring mechanisms, and immunomodulation. Five landmark papers reviewed.

Читать далее...

Stem Cells and Alzheimer’s Disease: A Patient’s Guide to What 2026 Research Shows

2026 patient guide to MSC therapy for Alzheimer’s disease: how it differs from lecanemab and donanemab, who is a candidate, what outcomes to expect, the 6 active clinical trials including NCT06775964 and the first MSC + antibody drug combination trial.

Читать далее...

The First FDA-Approved Stem Cell Therapy for Type 1 Diabetes: What Zimislecel Means for Patients in 2026

Zimislecel (VX-880) is the first stem cell-derived islet therapy to reach the FDA, and the September 2025 NEJM paper showed 12 of 12 patients achieving insulin independence. Here’s what it means for T1D patients in 2026, who qualifies, and what options exist in Thailand now.

Читать далее...

Can Stem Cell Exosomes Restore Hearing? What the 2026 Breakthrough Means for You

A 2026 Phase 1 trial showed that MSC-derived exosomes injected into the ear were safe and improved hearing in patients with sudden sensorineural hearing loss. Here’s what the breakthrough means and when it could be available.

Читать далее...
Top